[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Clinique Neuro-Outaouais\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100605228","repetitive-transcranial-magnetic-stimulation-rtms-in-ms-induced-spastic-paraparesis-100605228",false,"NCT07159789","Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis","Non-Invasive Neuromodulation in MS Induced Spastic Paraparesis","CeV","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Age ≥ 18 years and less than 71 years.\n3. Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).\n4. EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.\n5. Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening.\n6. Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic treatment of spasticity (baclofen, tizanidine, botulinum toxin etc.) during the study.\n7. No change in disease modifying therapy for at least 3 months prior to screening.\n8. Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol.\n\nExclusion Criteria:\n\n1. Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study.\n2. Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation.\n3. Pregnant or breastfeeding or intending to become pregnant during the study.\n4. Any previous rTMS therapy for any indication.\n5. Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker.\n6. Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study.","ALL","18 Years","70 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.",[28],"Multiple Sclerosis",[30,31,32,33,34,35],"rTMS","Neuromodulation","MS Induced Spastic Paraparesis","Spastic paresis","neural synchrony","neuroplasticity","RECRUITING","2025-12-03",{"date":39,"type":40},"2025-12-04","ACTUAL",{"date":42,"type":40},"2025-10-15",{"date":44,"type":22},"2028-03",{"name":46,"class":47},"Clinique Neuro-Outaouais","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100574890","phase-3-efgartigimod-in-ivig-dependent-myasthenia-gravis-patients-100574890","NCT06765161","Efgartigimod in IVIG Dependent Myasthenia Gravis Patients","Inclusion Criteria:\n\n* 1\\. Signed informed consent. 2. Age 18-80 years 3. Acetylcholine receptor antibody positive, myasthenia gravis patients, with stable disease for the past four or more months. Stable disease is defined as no change in dosage or interval in IVIG treatments and without any significant change in clinical status.\n\n  4\\. No modification or addition of NSISTs in the past six months 5. No modification or addition in corticosteroid therapy for the past three months 6. Myasthenia Gravis diagnosis was supported by abnormal neurotransmission test or history of improvement with AChE inhibitors.\n\n  7\\. Receiving chronic regular IVIG treatments for myasthenia gravis for the past year or more.\n\nExclusion Criteria:\n\n* 1\\. Patients with previous rituxan or eculizumab treatment or plasma exchange within the past six months 2. Patients with previous thymectomy within the past 3months 3. Patients that have active Hepatitis B, are seropositive for Hepatitis C or HIV or have latent, untreated or active TB or any other significant active infection 4. Patients that have at screening a serum IgG less than 6.0gm\u002FL or a history of chronic hypogammaglobulinemia from any cause.\n\n  5\\. Patients that are pregnant or considering becoming pregnant in the next 6 months.\n\n  6\\. Patients with severe renal impairment (eGFR less than 30ml\u002Fmin) 7. Patients who in the opinion of the investigator should not participate in the study.","80 Years",{"count":57,"type":22},30,[59],"PHASE3","This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will occur weekly throughout the study to week 26.",[62],"Myasthaenia Gravis",[64,65,66],"Myasthenia gravis","Vyvgart","IVIG","2025-07-25",{"date":69,"type":40},"2025-07-29",{"date":71,"type":40},"2025-02-06",{"date":73,"type":22},"2027-01-06",{"name":46,"class":47},""]